Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Revolutions Medical Corp. (RMCP.OB) Expanding into Brazil via Strategic Partnership

Revolutions Medical Corp.,, provider of a variety of safety/efficiency-oriented products and services to the medical industry, such as the proprietary and FDA-approved RevVac safety syringe (a safety blood drawing device), as well as a safety IV catheter and imaging solutions for MRIs and PACS, announced the signing of an agreement of understanding today with Santa Monica Pharmaceutica Ltda for the expressed purpose of setting up a manufacturing facility in Brazil to mass produce the RevVac safety syringe for global consumption.

The facility will also act as a strong foothold in the South American market for RMCP, by functioning as a distribution hub for the entire region and allowing the Company greater penetration into the $2B/year safety-engineered medical devices (SEMDs) market.

Commercial Director of Libra International, Nick Ogle, spoke of the “stringent vetting process” based on rigorously analyzed criteria used to select an ideal strategic partner since RMCP first came to them in December of this year; criteria which included a firm commitment to a rapid production schedule, proven distribution capacity, a similar market vector, and especially manufacturing expertise – for which Santa Monica Pharmaceutica Ltda has an outstanding reputation.

Mr. Ogle called the combination, of RMCP’s detail-oriented technological superiority and Santa Monica Pharmaceutica Ltda’s dynamic manufacturing capacity, a perfect strategic partnership.

CEO of RMCP, Ron Wheet, echoed these sentiments and hailed Santa Monica Pharmaceutica Ltda as an ideal solution for taking the Company’s RevVac safety syringe into full-scale production.

Mr. Wheet acknowledged the like-mindedness and shared vision of both firms regarding the proprietary, auto retractable, vacuum safety syringe technology behind the product, and pointed out the Brazilian government’s legislation of mandatory safety syringes, and forthcoming success of the pilot run (announced in December) as overwhelming evidence of the exciting potential for investors to get in on this technology before the product goes viral.

Managing Director of Libra International, Clive Davies, who recently moved to Brazil, characterized the agreement as the start of a huge win for everyone involved, especially Brazil, which was able to surmount foreign competition and secure the rights and prestige to host global production of this revolutionary product.

Please see disclaimer on QualityStocks website:


Disclosure: NO POSITIONS